In Brief: Boehringer Mannheim/PerSeptive Biosystems
This article was originally published in The Gray Sheet
Executive SummaryBoehringer Mannheim/PerSeptive Biosystems: Enter strategic alliance under which Boehringer gains worldwide co-exclusive distribution rights to Framingham, Massachusetts-based PerSeptive's Poros chromatography columns. In exchange, Boehringer agrees to purchase $2 mil. of PerSeptive common stock for $12.69 per share and obtains an option to buy an additional $1 mil. worth at the same price during the next 24 months. The companies say they also will conduct joint research and development of "advanced biochemical tools and reagents"...
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.